Cargando…

Long genes are more frequently affected by somatic mutations and show reduced expression in Alzheimer's disease: Implications for disease etiology

Aging, the greatest risk factor for Alzheimer's disease (AD), may lead to the accumulation of somatic mutations in neurons. We investigated whether somatic mutations, specifically in longer genes, are implicated in AD etiology. First, we modeled the theoretical likelihood of genes being affecte...

Descripción completa

Detalles Bibliográficos
Autores principales:	Soheili‐Nezhad, Sourena, van der Linden, Robert J., Olde Rikkert, Marcel, Sprooten, Emma, Poelmans, Geert
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Featured Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8048495/ https://www.ncbi.nlm.nih.gov/pubmed/33075204 http://dx.doi.org/10.1002/alz.12211

Ejemplares similares

Exploring the Genetic Link Between Thyroid Dysfunction and Common Psychiatric Disorders: A Specific Hormonal or a General Autoimmune Comorbidity
por: Soheili-Nezhad, Sourena, et al.
Publicado: (2023)

Imaging genomics discovery of a new risk variant for Alzheimer's disease in the postsynaptic SHARPIN gene
por: Soheili‐Nezhad, Sourena, et al.
Publicado: (2020)

Shared Genetic Etiology between Alzheimer’s Disease and Blood Levels of Specific Cytokines and Growth Factors
por: van der Linden, Robert J., et al.
Publicado: (2021)

Response to Mooij and van Trotsenburg re: “Exploring the Genetic Link Between Thyroid Dysfunction and Common Psychiatric Disorders: A Specific Hormonal or a General Autoimmune Comorbidity”
por: Medici, Marco, et al.
Publicado: (2023)

Memory enhancing drugs and Alzheimer’s Disease: Enhancing the self or preventing the loss of it?
por: Dekkers, Wim, et al.
Publicado: (2007)

Structural and Functional Reorganization of the Brain in Migraine Without Aura
por: Soheili-Nezhad, Sourena, et al.
Publicado: (2019)

Patients with Alzheimer's disease who carry the APOE ε4 allele benefit more from physical exercise
por: Jensen, Camilla Steen, et al.
Publicado: (2019)

Development of Written Materials for Participants in an Alzheimer's Disease and Related Dementias Screening Trial
por: Head, Katharine J, et al.
Publicado: (2022)

Clinical and cognitive characteristics of preclinical Alzheimer's disease in the Japanese Alzheimer's Disease Neuroimaging Initiative cohort
por: Ihara, Ryoko, et al.
Publicado: (2018)

The prevalence and biomarkers’ characteristic of rapidly progressive Alzheimer's disease from the Alzheimer's Disease Neuroimaging Initiative database
por: Ba, Maowen, et al.
Publicado: (2017)

Intranasal rifampicin for Alzheimer's disease prevention
por: Umeda, Tomohiro, et al.
Publicado: (2018)

Estrogen activates Alzheimer's disease genes
por: Ratnakumar, Abhirami, et al.
Publicado: (2019)

Alzheimer's disease assessment scale-cognitive 11-item progression model in mild-to-moderate Alzheimer's disease trials of bapineuzumab
por: Samtani, Mahesh N., et al.
Publicado: (2015)

Teaching More by Grading Less (or Differently)
por: Schinske, Jeffrey, et al.
Publicado: (2014)

Alzheimer's disease drug development pipeline: 2018
por: Cummings, Jeffrey, et al.
Publicado: (2018)

Alzheimer's disease drug development pipeline: 2019
por: Cummings, Jeffrey, et al.
Publicado: (2019)

Synergism of antihypertensives and cholinesterase inhibitors in Alzheimer's disease
por: Hu, Ziheng, et al.
Publicado: (2018)

Preclinical Alzheimer's disease and longitudinal driving decline
por: Roe, Catherine M., et al.
Publicado: (2016)

Progranulin mutations in clinical and neuropathological Alzheimer's disease
por: Vardarajan, Badri N., et al.
Publicado: (2022)

Identification of prognostic factors to predict cognitive decline of patients with early Alzheimer's disease in the Japanese Alzheimer's Disease Neuroimaging Initiative study
por: Yagi, Takuya, et al.
Publicado: (2019)

Shared genetic etiology between Parkinson’s disease and blood levels of specific lipids
por: Xicoy, Helena, et al.
Publicado: (2021)

Neurogenic bladder: etiology and assessment
por: Bauer, Stuart B.
Publicado: (2008)

Contribution of Alzheimer's biomarkers and risk factors to cognitive impairment and decline across the Alzheimer's disease continuum
por: Tosun, Duygu, et al.
Publicado: (2021)

Dissociation of Down syndrome and Alzheimer's disease effects with imaging
por: Matthews, Dawn C., et al.
Publicado: (2016)

Cross-validation of optimized composites for preclinical Alzheimer's disease
por: Donohue, Michael C., et al.
Publicado: (2016)

Institutionalization risk and costs associated with agitation in Alzheimer's disease
por: Cloutier, Martin, et al.
Publicado: (2019)

The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer's disease
por: Simrén, Joel, et al.
Publicado: (2021)

Midlife lipid and glucose levels are associated with Alzheimer's disease
por: Zhang, Xiaoling, et al.
Publicado: (2022)

Why illness is more important than disease in old age
por: Olde Rikkert, Marcel G M, et al.
Publicado: (2022)

Normal cerebrospinal fluid concentrations of PDGFRβ in patients with cerebral amyloid angiopathy and Alzheimer's disease
por: De Kort, Anna M., et al.
Publicado: (2021)

CVN‐AD Alzheimer's mice show premature reduction in neurovascular coupling in response to spreading depression and anoxia compared to aged controls
por: Turner, Dennis A., et al.
Publicado: (2021)

Effects of traumatic brain injury and posttraumatic stress disorder on development of Alzheimer's disease in Vietnam Veterans using the Alzheimer's Disease Neuroimaging Initiative: Preliminary report
por: Weiner, Michael W., et al.
Publicado: (2017)

Glycoscience: Integrating a Key Macromolecule More Fully into the Curriculum
por: Bowman, Katherine, et al.
Publicado: (2013)

Alzheimer's disease Archimedes condition-event simulator: Development and validation
por: Kansal, Anuraag R., et al.
Publicado: (2018)

Quantile regression to characterize solanezumab effects in Alzheimer's disease trials
por: Chen, Yun-Fei, et al.
Publicado: (2016)

Measuring informed consent capacity in an Alzheimer's disease clinical trial
por: Guarino, Peter D., et al.
Publicado: (2016)

Central pharmacodynamic activity of solanezumab in mild Alzheimer's disease dementia
por: Willis, Brian A., et al.
Publicado: (2018)

An amylin analog used as a challenge test for Alzheimer's disease
por: Zhu, Haihao, et al.
Publicado: (2017)

Enrichment factors for clinical trials in mild-to-moderate Alzheimer's disease
por: Ballard, Clive, et al.
Publicado: (2019)

Using data science to diagnose and characterize heterogeneity of Alzheimer's disease
por: Ang, Ting F.A., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_boh65gi6esnrpmbiso5oe31tdn